We are focused on the discovery, development and
commercialization of first-in-class treatments for
Leveraging the body’s
VBL’s clinical pipeline is based on two platform technologies that enhance natural physiologic and genetic regulatory elements.
Our product candidates
Our lead candidate is VB-111, a gene-based biologic agent for solid tumor indications. VB-111 pivotal Phase 3 GLOBE trial in rGBM is ongoing under a special protocol assessment granted by the FDA.